Drug–gene and drug–drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19(1), 69–76 (2017).
  MedlineGoogle Scholar
• 2 Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234–242 (2008). •• Formed the basis of how we assigned activity scores based on CYP2D6 genotype.
  Medline CASGoogle Scholar
• 3 Dean L. Tramadol therapy and CYP2D6 genotype. In: Medical Genetics Summaries. Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A (Eds). National Center for Biotechnology Information, MD, USA (2012).
  Google Scholar
• 4 Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95(4), 376–382 (2014). • Details the Clinical Pharmacogenomics Implementation Consortium guidelines for CYP2D6 and codeine therapy.
  Medline CASGoogle Scholar
• 5 Smith DM, Weitzel KW, Cavallari LH, Elsey AR, Schmidt SO. Clinical application of pharmacogenetics in pain management. Per. Med. 15(2), 117–126 (2018).
  CASGoogle Scholar
• 6 Eadon MT, Desta Z, Levy KD et al. Implementation of a pharmacogenomics consult service to support the INGENIOUS trial. Clin. Pharmacol. Ther. 100(1), 63–66 (2016). •• Describes the trial design and clinical support within the INGENIOUS study.
  Medline CASGoogle Scholar
• 7 Bell GC, Crews KR, Wilkinson MR et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. 21(e1), e93–e99 (2014).
  MedlineGoogle Scholar
• 8 Gammal RS, Crews KR, Haidar CE et al. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics 138(1), e20153479 (2016).
  MedlineGoogle Scholar
• 9 Danahey K, Borden BA, Furner B et al. Simplifying the use of pharmacogenomics in clinical practice: building the genomic prescribing system. J. Biomed. Inform. 75, 110–121 (2017).
  MedlineGoogle Scholar
• 10 Reinecke H, Weber C, Lange K, Simon M, Stein C, Sorgatz H. Analgesic efficacy of opioids in chronic pain: recent meta-analyses. Br. J. Pharmacol. 172(2), 324–333 (2015).
  Medline CASGoogle Scholar
• 11 Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm. Rep. 65(1), 1–49 (2016).
  MedlineGoogle Scholar
• 12 Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann. Intern. Med. 155(5), 325–328 (2011).
  MedlineGoogle Scholar
• 13 Franklin GM, American Academy Of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 83(14), 1277–1284 (2014).
  Medline CASGoogle Scholar
• 14 Watkins EA, Wollan PC, Melton LJ 3rd, Yawn BP. A population in pain: report from the Olmsted County health study. Pain Med. 9(2), 166–174 (2008).
  MedlineGoogle Scholar
• 15 Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain 16(8), 769–780 (2015).
  MedlineGoogle Scholar
• 16 Pitcher MH, Von Korff M, Bushnell MC, Porter L. Prevalence and profile of high-impact chronic pain in the United States. J. Pain 20(2), 146–160 (2019).
  MedlineGoogle Scholar
• 17 Kennedy J, Roll JM, Schraudner T, Murphy S, Mcpherson S. Prevalence of persistent pain in the U.S. adult population: new data from the 2010 national health interview survey. J. Pain 15(10), 979–984 (2014).
  MedlineGoogle Scholar
• 18 Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. Am. J. Prev. Med. 49(3), 409–413 (2015).
  MedlineGoogle Scholar
• 19 Dressler LG, Bell GC, Ruch KD, Retamal JD, Krug PB, Paulus RA. Implementing a personalized medicine program in a community health system. Pharmacogenomics 19(17), 1345–1356 (2018).
  CASGoogle Scholar
• 20 Dong OM, Li A, Suzuki O et al. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics doi:10.2217/pgs-2018-0049 (2018) (Epub ahead of print).
  Google Scholar
• 21 Peiro AM, Margarit C, A LL. What is the future of pharmacogenomics in pain management? Pharmacogenomics 18(2), 101–103 (2017).
  CASGoogle Scholar
• 22 Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT. Lessons learned when introducing pharmacogenomic panel testing into clinical practice. Value Health 20(1), 54–59 (2017).
  MedlineGoogle Scholar
• 23 Blagec K, Kuch W, Samwald M. The Importance of gene-drug–drug-interactions in pharmacogenomics decision support: an analysis based on Austrian claims data. Stud. Health Technol. Inform. 236, 121–127 (2017).
  MedlineGoogle Scholar
• 24 Gaedigk A, Dinh JC, Jeong H, Prasad B, Leeder JS. Ten years’ experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics. J. Pers. Med. 8(2), doi: 10.3390/jpm8020015 (2018).
  MedlineGoogle Scholar
• 25 Knisely MR, Carpenter JS, Draucker CB et al. CYP2D6 drug–gene and drug–drug–gene interactions among patients prescribed pharmacogenetically actionable opioids. Appl. Nurs. Res. 38, 107–110 (2017).
  MedlineGoogle Scholar
• 26 Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y. Impact of CYP2D6 functional allelic variations on phenoconversion and drug–drug interactions. Clin. Pharmacol. Ther. doi:10.1002/cpt (2017) (Epub ahead of print).
  MedlineGoogle Scholar
• 27 Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 18(7), 701–739 (2017). • Reviews the interacting sites within the IGNITE network.
  CASGoogle Scholar
• 28 Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br. J. Clin. Pharmacol. 79(2), 222–240 (2015).
  MedlineGoogle Scholar
• 29 Sperber NR, Carpenter JS, Cavallari LH et al. Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Med. Genomics 10(1), 35 (2017).
  MedlineGoogle Scholar
• 30 Volpi S, Bult CJ, Chisholm RL et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin. Pharmacol. Ther. 103(5), 778–786 (2018).
  MedlineGoogle Scholar
• 31 Orlando LA, Sperber NR, Voils C et al. Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network's Common Measures Working Group. Genet. Med. 20(6), 655–663 (2017).
  MedlineGoogle Scholar
• 32 Pierson RC, Gufford BT, Desta Z, Eadon MT. Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics 18(9), 835–841 (2017).
  CASGoogle Scholar
• 33 Carpenter JS, Rosenman MB, Knisely MR, Decker BS, Levy KD, Flockhart DA. Pharmacogenomically actionable medications in a safety net health care system. SAGE Open Med. 4, 2050312115624333 (2016).
  Google Scholar
• 34 Levy KD, Decker BS, Carpenter JS et al. Prerequisites to implementing a pharmacogenomics program in a large healthcare system. Clin. Pharmacol. Ther. 96(3), 307–309 (2014).
  Medline CASGoogle Scholar
• 35 Ford I, Norrie J. Pragmatic trials. N. Engl. J. Med. 375(5), 454–463 (2016). • Includes the Dutch Pharmacogenomic Working Group recommendations for many drugs including tramadol.
  MedlineGoogle Scholar
• 36 Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 102(1), 146–150 (2006).
  Medline CASGoogle Scholar
• 37 Stamer UM, Lehnen K, Hothker F et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105(1-2), 231–238 (2003).
  Medline CASGoogle Scholar
• 38 Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects – the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur. J. Clin. Pharmacol. 61(4), 257–266 (2005).
  Medline CASGoogle Scholar
• 39 Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 82(1), 41–47 (2007).
  Medline CASGoogle Scholar
• 40 Swen JJ, Nijenhuis M, De Boer A et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662–673 (2011).
  Medline CASGoogle Scholar
• 41 Madadi P, Ross CJ, Hayden MR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clin. Pharmacol. Ther. 85(1), 31–35 (2009).
  Medline CASGoogle Scholar
• 42 Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 89(6), 839–845 (2002).
  Medline CASGoogle Scholar
• 43 Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7(4), 257–265 (2007).
  Medline CASGoogle Scholar
• 44 Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827–2831 (2004).
  Medline CASGoogle Scholar
• 45 Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006).
  MedlineGoogle Scholar
• 46 Zedler B, Xie L, Wang L et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med. 15(11), 1911–1929 (2014).
  MedlineGoogle Scholar
• 47 Mahowald ML, Singh JA, Majeski P. Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum. 52(1), 312–321 (2005).
  MedlineGoogle Scholar
• 48 Merritt J RJ, Charbonneau E. Senate bill 226 (2017). https://legiscan.com/IN/bill/SB0226/2017.
  Google Scholar
• 49 Moller HJ. Effectiveness studies: advantages and disadvantages. Dialogues Clin. Neurosci. 13(2), 199–207 (2011).
  MedlineGoogle Scholar
• 50 Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin. Trials 12(5), 436–441 (2015).
  MedlineGoogle Scholar
• 51 Drewes AM, Jensen RD, Nielsen LM et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br. J. Clin. Pharmacol. 75(1), 60–78 (2013).
  Medline CASGoogle Scholar
• 52 Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP 450 testing in the clinical setting. Mol. Diagn. Ther. 17(3), 165–184 (2013).
  Medline CASGoogle Scholar
• 53 Chang KL, Weitzel K, Schmidt S. Pharmacogenetics: using genetic information to guide drug therapy. Am. Fam. Physician 92(7), 588–594 (2015).
  MedlineGoogle Scholar